PA
MAZE

Profund Advisors’s Maze Therapeutics MAZE Stock Holding History

Profund Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
+11,025
New +$289K 0.01% 748
2026
Q1 		– Sell
-6,016
Closed -$249K – 1316
2025
Q4 		$249K Buy
+6,016
New +$207K 0.01% 1012

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Profund Advisors's MAZE Position: Q2 2026 in Review

Profund Advisors opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 11,025 shares worth $329K. The stake represents 0.01% of the portfolio and ranks #748 among its holdings. This is a return to the name: Profund Advisors previously reported a position in MAZE as recently as Q4 2025.

Profund Advisors first reported a position in MAZE in Q4 2025 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Profund Advisors held 11,025 shares of Maze Therapeutics worth $329K as of Q2 2026.
  • Maze Therapeutics was a new Profund Advisors position in Q2 2026.
  • Maze Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #748 holding.
  • Profund Advisors first reported a position in Maze Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.